Cargando…
Twenty Years of Experience on Stem Cell Transplantation in Iran
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a new window to therapy of many diseases. From March 1991 through April 2011, a total of 3237 HSCT were performed in the Hematology-Oncology and Stem Cell Transplantation Research Center, affiliated to Tehran University of Medical Science...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652510/ https://www.ncbi.nlm.nih.gov/pubmed/23682320 http://dx.doi.org/10.5812/ircmj.1915 |
_version_ | 1782269323855790080 |
---|---|
author | Ghavamzadeh, Ardeshir Alimoghaddam, Kamran Ghaffari, Fatemeh Derakhshandeh, Roshanak Jalali, Arash Jahani, Mohammad |
author_facet | Ghavamzadeh, Ardeshir Alimoghaddam, Kamran Ghaffari, Fatemeh Derakhshandeh, Roshanak Jalali, Arash Jahani, Mohammad |
author_sort | Ghavamzadeh, Ardeshir |
collection | PubMed |
description | BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a new window to therapy of many diseases. From March 1991 through April 2011, a total of 3237 HSCT were performed in the Hematology-Oncology and Stem Cell Transplantation Research Center, affiliated to Tehran University of Medical Sciences. Here we report 20 years experience of HSCT. OBJECTIVES: Our strategy and aim include the protraction of cytogenetic and molecular biological diagnostic tests, the expansion of the first Iranian Cord Blood Bank (ICBB) and development of the first Iranian Stem Cell Donor Program (ISCDP), and improvement the researches in new therapeutic fields. PATIENTS AND METHODS: Totally, 3237 patients were undergone HSCT. Of these transplants, 2205 were allogeneic stem cell transplantation, 1016 autologous and 16 syngeneic. Among 2205 patients who were undergone allogenic-HSCT, 34 received cord blood stem cells as stem cell source for transplantation. It is important to point out that cord blood bank at our center provides reliable storage of cord blood stem cells for our patients. Stem cell transplantation was performed for treatment of various diseases such as acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphoblastic leukemia, beta-thalassemia major, sickle- cell thalassemia, sickle- cell disease, multiple myeloma, myelodysplasia, mucopolysaccharidosis, paroxysmal nocturnal hemoglobinuria, non-Hodgkin’s lymphoma, Hodgkin’s disease, severe aplastic anemia, plasma cell leukemia, Niemann-Pick disease, Fanconi anemia, severe combined immunodeficiency, congenital neutropenia, leukocyte adhesion deficiencies, Chediak-Higashi syndrome, osteopetrosis, histiocytosis X, Hurler syndrome, amyloidosis, systemic sclerosis, breast cancer, Ewing's sarcoma, testicular cancer, germ cell tumors, neuroblastoma, medulloblastoma, renal cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, Wilms’ tumor, rhabdomyosarcoma, pancreatoblastoma, and multiple sclerosis. Also, we had 220 cellular therapies for post-myocardial infarction, multiple sclerosis, cirrhosis, head of femur necrosis, Diabetes Mellitus and GvHD treatment. 45 patients were undergone retransplantation in this center. RESULTS: About 78.2% of the patients (2530 of 3237) remained alive between one to 211 months after stem cell transplantation. Nearly, 21.8% (707) of our patients died after stem cell transplantation. The main causes of death were relapse, infection, hemorrhagic cystitis, graft-versus- host disease and etc. CONCLUSIONS: In Iran, HSCT has been successfully adapted in routine clinical care. Recently, new methods such as double cord blood and haploidentical transplantation have been used to treat many life-threatening diseases. |
format | Online Article Text |
id | pubmed-3652510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-36525102013-05-16 Twenty Years of Experience on Stem Cell Transplantation in Iran Ghavamzadeh, Ardeshir Alimoghaddam, Kamran Ghaffari, Fatemeh Derakhshandeh, Roshanak Jalali, Arash Jahani, Mohammad Iran Red Crescent Med J Research Article BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a new window to therapy of many diseases. From March 1991 through April 2011, a total of 3237 HSCT were performed in the Hematology-Oncology and Stem Cell Transplantation Research Center, affiliated to Tehran University of Medical Sciences. Here we report 20 years experience of HSCT. OBJECTIVES: Our strategy and aim include the protraction of cytogenetic and molecular biological diagnostic tests, the expansion of the first Iranian Cord Blood Bank (ICBB) and development of the first Iranian Stem Cell Donor Program (ISCDP), and improvement the researches in new therapeutic fields. PATIENTS AND METHODS: Totally, 3237 patients were undergone HSCT. Of these transplants, 2205 were allogeneic stem cell transplantation, 1016 autologous and 16 syngeneic. Among 2205 patients who were undergone allogenic-HSCT, 34 received cord blood stem cells as stem cell source for transplantation. It is important to point out that cord blood bank at our center provides reliable storage of cord blood stem cells for our patients. Stem cell transplantation was performed for treatment of various diseases such as acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphoblastic leukemia, beta-thalassemia major, sickle- cell thalassemia, sickle- cell disease, multiple myeloma, myelodysplasia, mucopolysaccharidosis, paroxysmal nocturnal hemoglobinuria, non-Hodgkin’s lymphoma, Hodgkin’s disease, severe aplastic anemia, plasma cell leukemia, Niemann-Pick disease, Fanconi anemia, severe combined immunodeficiency, congenital neutropenia, leukocyte adhesion deficiencies, Chediak-Higashi syndrome, osteopetrosis, histiocytosis X, Hurler syndrome, amyloidosis, systemic sclerosis, breast cancer, Ewing's sarcoma, testicular cancer, germ cell tumors, neuroblastoma, medulloblastoma, renal cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, Wilms’ tumor, rhabdomyosarcoma, pancreatoblastoma, and multiple sclerosis. Also, we had 220 cellular therapies for post-myocardial infarction, multiple sclerosis, cirrhosis, head of femur necrosis, Diabetes Mellitus and GvHD treatment. 45 patients were undergone retransplantation in this center. RESULTS: About 78.2% of the patients (2530 of 3237) remained alive between one to 211 months after stem cell transplantation. Nearly, 21.8% (707) of our patients died after stem cell transplantation. The main causes of death were relapse, infection, hemorrhagic cystitis, graft-versus- host disease and etc. CONCLUSIONS: In Iran, HSCT has been successfully adapted in routine clinical care. Recently, new methods such as double cord blood and haploidentical transplantation have been used to treat many life-threatening diseases. Kowsar 2013-02-05 2013-02 /pmc/articles/PMC3652510/ /pubmed/23682320 http://dx.doi.org/10.5812/ircmj.1915 Text en Copyright © 2013, Iranian Red Crescent Medical Journal http://creativecommons.org/licenses/by/3/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ghavamzadeh, Ardeshir Alimoghaddam, Kamran Ghaffari, Fatemeh Derakhshandeh, Roshanak Jalali, Arash Jahani, Mohammad Twenty Years of Experience on Stem Cell Transplantation in Iran |
title | Twenty Years of Experience on Stem Cell Transplantation in Iran |
title_full | Twenty Years of Experience on Stem Cell Transplantation in Iran |
title_fullStr | Twenty Years of Experience on Stem Cell Transplantation in Iran |
title_full_unstemmed | Twenty Years of Experience on Stem Cell Transplantation in Iran |
title_short | Twenty Years of Experience on Stem Cell Transplantation in Iran |
title_sort | twenty years of experience on stem cell transplantation in iran |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652510/ https://www.ncbi.nlm.nih.gov/pubmed/23682320 http://dx.doi.org/10.5812/ircmj.1915 |
work_keys_str_mv | AT ghavamzadehardeshir twentyyearsofexperienceonstemcelltransplantationiniran AT alimoghaddamkamran twentyyearsofexperienceonstemcelltransplantationiniran AT ghaffarifatemeh twentyyearsofexperienceonstemcelltransplantationiniran AT derakhshandehroshanak twentyyearsofexperienceonstemcelltransplantationiniran AT jalaliarash twentyyearsofexperienceonstemcelltransplantationiniran AT jahanimohammad twentyyearsofexperienceonstemcelltransplantationiniran |